Table of Contents

• Trial overview
• Eye disease studies
• Comparative and dose studies
• Special patient groups
• Main endpoints measured in the trials
• What these trials mean for patients

Trial overview

The trial data show that Aflibercept is being studied mainly in eye diseases, with most studies in Phase 3 and a smaller number in Phase 2.^[1] The largest groups include people with wet or neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and retinopathy of prematurity.^[1] Some trials also compare Aflibercept with placebo, sham injection, or other active treatments, while others compare different doses or treatment schedules.^[1]

The studies are mostly interventional, which means researchers give a treatment and then measure what happens.^[1] Enrollment ranges from small studies with a few dozen people to large studies with hundreds of participants.^[1]

Eye disease studies

Several trials focus on wet age-related macular degeneration, also called neovascular AMD or nAMD, which is a serious eye disease that can reduce central vision.^[1] In these studies, Aflibercept is used as the comparison treatment to test new medicines or new treatment plans, such as EYP-1901, 4D-150, RGX-314, OPT-302, or faricimab in selected groups.^[1]

Other studies look at diabetic macular edema, which means swelling in the center of the retina caused by diabetes.^[1] These trials compare Aflibercept with newer treatments or different dosing approaches and usually measure whether vision stays the same or improves over time.^[1]

There is also a study in macular edema secondary to retinal vein occlusion, where a blocked retinal vein causes swelling and vision loss.^[1] That trial compares Aflibercept 8 mg with Aflibercept 2 mg and looks at whether the higher dose can give similar vision results with a different injection schedule.^[1]

One Phase 3 study examines retinopathy of prematurity, a condition seen in premature babies in which the retinal blood vessels do not develop normally.^[1] The extension studies focus on long-term vision and safety in children who already took part in earlier treatment studies.^[1]

Comparative and dose studies

Some trials are designed to compare Aflibercept with another treatment or with no active drug.^[1] For example, the macular telangiectasia type 1 study compares Aflibercept with placebo and measures change in central retinal thickness, which is the thickness of the center part of the retina.^[1]

Other trials compare Aflibercept with other medicines used in eye care, such as bevacizumab, in neovascular age-related macular degeneration.^[1] A different study looks at whether people who already needed frequent treatment can have longer treatment intervals with Aflibercept 8 mg while keeping the eye dry, meaning without retinal fluid.^[1]

One study also measures blood levels after high-dose Aflibercept is given in both eyes of people with diabetic macular edema or neovascular age-related macular degeneration.^[1] This is a pharmacokinetic study, which means it checks how much of the medicine is found in the body after treatment.^[1]

Special patient groups

Some studies include special groups of patients rather than only typical adult eye-disease populations.^[1] The retinopathy of prematurity studies are important because they involve children and track longer-term vision and safety outcomes.^[1]

Another completed trial studied prevention of neovascular glaucoma after proton therapy in people with large choroid melanoma.^[1] In that study, Aflibercept was compared with a false injection to see whether preventive treatment could lower the risk of this serious eye complication.^[1]

The trial list also includes a real-world study using artificial intelligence to help manage active neovascular AMD.^[1] That study looks at the number of anti-VEGF injections, which reflects treatment burden and how often patients need visits and injections.^[1]

Main endpoints measured in the trials

Many of the trials use BCVA, or best-corrected visual acuity, as a main outcome.^[1] This is a standard way to measure how well a person can see after the best correction is used.

Other common endpoints include change in retinal thickness, proportion of eyes without disease activity, number of injections, and time to disease progression.^[1] Some studies also measure long-term safety outcomes, such as adverse events, serious adverse events, or eye-specific side effects.^[1]

In some trials, the goal is non-inferiority, which means the new approach is tested to see if it works at least almost as well as the comparison treatment.^[1] In others, the goal is equivalence, which means the study asks whether two treatments perform similarly.^[1]

What these trials mean for patients

Overall, the trial program for Aflibercept is broad and mainly focused on preserving vision, reducing retinal swelling, and finding better treatment schedules.^[1] The studies are not all asking the same question, but they share a common goal: to understand where Aflibercept fits best in eye disease care and how it compares with newer or alternative options.^[1]

For patients, this means the research includes different ages, different eye diseases, and different treatment goals, from short-term vision changes to longer-term safety and durability.^[1] The trial data show that Aflibercept is being used both as a treatment being tested directly and as a standard treatment used for comparison in studies of new therapies.^[1]